Sun Pharmaceutical Industries Limited

SUN HOUSE, CTS No. 201 B/1,

Western Express Highway, Goregaon (E),

Mumbai 400063, India

Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343

Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050



FOR IMMEDIATE RELEASE

Sun Pharma Amongst Top 5% Of Global Pharmaceutical Companies In S&P Global Sustainability Yearbook 2025

Mumbai, February 17, 2025: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") today announced that it has been included in the S&P Global Sustainability Yearbook 2025. Sun Pharma has qualified in the Top 5% of pharmaceutical companies assessed by S&P globally for this Yearbook.

Within respective industries, this Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability. This recognition attests to Sun Pharma's commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses.

Dilip Shanghvi, Chairman & Managing Director of the Company said, "We continue to focus on delivering sustainable outcomes for all our stakeholders. Sustainability is an integral part of our way of doing business and we remain steadfast in our commitment to align our strategy with universal ESG principles and to undertake the requisite steps for further advancing societal goals."

Based on the S&P Global Corporate Sustainability Assessment (CSA) for 2024, over 7,690 companies globally were assessed for The Sustainability Yearbook 2025. Out of these, 780 companies have qualified for inclusion in The Sustainability Yearbook 2025 globally.

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA

Reaching People. Touching Live:

Sun Pharmaceutical Industries Limited

SUN HOUSE, CTS No. 201 B/1,

Western Express Highway, Goregaon (E),

Mumbai 400063, India

Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343

Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050



Disclaimer

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).

Contacts: Sun Pharma

Investors:

Dr. Abhishek Sharma
Tel + 91 22 4324 4324, Ext 2929
Tel Direct + 91 22 43242929 **Mobile** + 91 98196 86016 **E mail** abhi.sharma@sunpharma.com

Media:

Gaurav Chugh
Tel +91 22 4324 4324, Ext 5373
Tel Direct +91 22 4324 5373 **Mobile** +91 98104 71414 **E mail** gaurav.chugh@sunpharma.com